-
公开(公告)号：US20210115038A1
公开(公告)日：2021-04-22
申请号：US17073017
申请日：2020-10-16
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD
Inventor： Gaurav Sanjivkumar Sheth , Sabbirhusen Yusufbhai Chimanwala , Tushar Mukund Jarag , Aishwarya Hampiholi , Saikat Maity , Prabal Sengupta , Gulamnizami Abdulsattar Qureshi , Umesh Vishnu Chaudhari , Raj Gopal Venkat , V.S.N. Murty Kadiyala , Sairam VVM Kalapatapu , Vaibhav Jain , Trinadha Rao Chitturi
IPC: C07D471/04 , C07D295/182 , C07D213/81 , C07D213/74 , C07D401/14 , C07D409/12 , C07D493/08 , C07D209/42 , C07D209/18 , C07D401/12 , C07D209/08
Abstract: The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans.
-
公开(公告)号：US20180036243A1
公开(公告)日：2018-02-08
申请号：US15552966
申请日：2016-02-25
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
Inventor： Madhusudhan BOMMAGANI , Subhas Balaram BHOWMICK , Prashant KANE , Vaibhav DUBEY
CPC classification number: A61K9/146 , A61K9/0014 , A61K9/06 , A61K9/10 , A61K9/122 , A61K31/65 , A61K47/14 , Y02A50/473
Abstract: The present invention relates to a nanoparticulate topical composition comprising (i) nanoparticles of a water soluble and water susceptible active ingredient or its pharmaceutically acceptable salt, having a particle size distribution such that 90% of the particles are less than 1000 nm, (ii) one or more wetting agent and (iii) a non-aqueous liquid vehicle, wherein the composition is free of water.The present invention also relates to a method of treating acne, rosacea, impetigo or a skin disease caused by a bacteria, by topical application of a nanoparticulate topical composition comprising nanoparticles of a water soluble and water susceptible active ingredient or its pharmaceutically acceptable salt, having a particle size distribution such that 90% of the particles are less than 1000 nm.
-
公开(公告)号：US09610269B2
公开(公告)日：2017-04-04
申请号：US14107245
申请日：2013-12-16
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
IPC: A61K31/197 , A61K9/00 , A61K9/24 , A61K9/48 , A61K9/50
CPC classification number: A61K31/197 , A61K9/006 , A61K9/0065 , A61K9/209 , A61K9/4866 , A61K9/4891 , A61K9/5047
Abstract: The present invention discloses a method of treating a disease condition susceptible to baclofen therapy, said method comprising orally administering once-a-day in the evening a controlled release drug delivery system comprising baclofen or its pharmaceutically acceptable salt or its derivatives and pharmaceutically acceptable excipients.
-
公开(公告)号：US20170087089A1
公开(公告)日：2017-03-30
申请号：US15282267
申请日：2016-09-30
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD
IPC: A61K9/127 , A61K31/7048
CPC classification number: A61K9/127 , A61K9/1277 , A61K31/7048
Abstract: The present invention relates to a process for the preparation of unilamellar liposomal composition of a polyene antibiotic drug. The present invention further relates to liposomal composition of a polyene antibiotic drug that is stable.
-
15.发明申请公开(公告)号：US20140105973A1
公开(公告)日：2014-04-17
申请号：US14107245
申请日：2013-12-16
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
IPC: A61K31/197 , A61K9/00
CPC classification number: A61K31/197 , A61K9/006 , A61K9/0065 , A61K9/209 , A61K9/4866 , A61K9/4891 , A61K9/5047
Abstract: The present invention discloses a method of treating a disease condition susceptible to baclofen therapy, said method comprising orally administering once-a-day in the evening a controlled release drug delivery system comprising baclofen or its pharmaceutically acceptable salt or its derivatives and pharmaceutically acceptable excipients.
Abstract translation: 本发明公开了一种治疗对巴氯芬治疗敏感的疾病状况的方法，所述方法包括在晚上一天一次口服给予包含巴氯芬或其药学上可接受的盐或其衍生物和药学上可接受的赋形剂的控释药物递送系统。
-
Patent Agency Ranking
公开(公告)号：US20240180902A1
公开(公告)日：2024-06-06
申请号：US18441901
申请日：2024-02-14
Applicant: Sun Pharma Advanced Research Company Ltd.
Inventor： Ajay Jaysingh KHOPADE , Arindam HALDER
CPC classification number: A61K31/498 , A61K9/0048 , A61K9/0051 , A61K9/08 , A61K9/1635 , A61K9/5176 , A61K45/06 , B01J39/20
Abstract: The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.
-
公开(公告)号：US11813252B2
公开(公告)日：2023-11-14
申请号：US17747472
申请日：2022-05-18
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
Inventor： Nitin Krishnaji Damle , Sanjay Nandlalji Mandhane , Manoj Atmaramji Upadhya , Sameer Vishwanath Mehetre , Gajanan Uttamrao Chidrewar , Prabal Sengupta , Trinadha Rao Chitturi
Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I
wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen;
or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl;
R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.-
公开(公告)号：US11583522B2
公开(公告)日：2023-02-21
申请号：US17061139
申请日：2020-10-01
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
Inventor： Nitin Krishnaji Damle , Sanjay Nandlalji Mandhane , Manoj Atmaramji Upadhya , Sameer Vishwanath Mehetre , Gajanan Uttamrao Chidrewar , Prabal Sengupta , Trinadha Rao Chitturi
Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US10413543B2
公开(公告)日：2019-09-17
申请号：US15042479
申请日：2016-02-12
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
Inventor： Nitin Bhalachandra Dharmadikari , Yashoraj Zala , Ashwini Gadkari
IPC: A61K31/505 , A61K9/16 , A61K9/50 , A61K9/48
Abstract: A stable multi-particulate pharmaceutical composition comprising pellets, the pellets comprising a mixture of rosuvastatin or its pharmaceutically acceptable salts as a sole active ingredient, one or more osmotic release modifiers and one or more stabilizers.
-
公开(公告)号：US09642811B2
公开(公告)日：2017-05-09
申请号：US14667826
申请日：2015-03-25
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
IPC: A61K9/28 , A61K9/48 , A61K31/137 , A61K31/5517 , A61K9/20 , A61K31/433 , A61K9/50
CPC classification number: A61K9/2081 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K9/2846 , A61K9/4808 , A61K9/485 , A61K9/4858 , A61K9/4866 , A61K9/5026 , A61K31/135 , A61K31/137 , A61K31/167 , A61K31/433 , A61K31/5517 , A61K2300/00
Abstract: An abuse deterrent immediate release biphasic matrix solid dosage form that releases the drug at a desired rate for quick onset of action when a single unit or prescribed units of the dosage form are orally administered but exhibits a reduced rate of release when more than the prescribed number of units, are administered.
-
-
-
-
-
-
-
-
-
Search Results
40
records
(took 0.043 seconds)
